These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31699406)

  • 1. Why Are Some Driver Mutations Rare?
    Nussinov R; Tsai CJ; Jang H
    Trends Pharmacol Sci; 2019 Dec; 40(12):919-929. PubMed ID: 31699406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoinhibition can identify rare driver mutations and advise pharmacology.
    Nussinov R; Tsai CJ; Jang H
    FASEB J; 2020 Jan; 34(1):16-29. PubMed ID: 31914624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes.
    Agajanian S; Odeyemi O; Bischoff N; Ratra S; Verkhivker GM
    J Chem Inf Model; 2018 Oct; 58(10):2131-2150. PubMed ID: 30253099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Latent drivers' expand the cancer mutational landscape.
    Nussinov R; Tsai CJ
    Curr Opin Struct Biol; 2015 Jun; 32():25-32. PubMed ID: 25661093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of constrained cancer driver genes based on mutation timing.
    Sakoparnig T; Fried P; Beerenwinkel N
    PLoS Comput Biol; 2015 Jan; 11(1):e1004027. PubMed ID: 25569148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering.
    Van den Eynden J; Fierro AC; Verbeke LP; Marchal K
    BMC Bioinformatics; 2015 Apr; 16():125. PubMed ID: 25903787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers.
    Nussinov R; Jang H; Tsai CJ; Cheng F
    PLoS Comput Biol; 2019 Mar; 15(3):e1006658. PubMed ID: 30921324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.
    Bányai L; Trexler M; Kerekes K; Csuka O; Patthy L
    Elife; 2021 Jan; 10():. PubMed ID: 33427197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploiting rare driver mutations for precision cancer medicine.
    Scholl C; Fröhling S
    Curr Opin Genet Dev; 2019 Feb; 54():1-6. PubMed ID: 30844512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating growth patterns and driver effects in tumor evolution from individual samples.
    Salichos L; Meyerson W; Warrell J; Gerstein M
    Nat Commun; 2020 Feb; 11(1):732. PubMed ID: 32024824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDENTIFY CANCER DRIVER GENES THROUGH SHARED MENDELIAN DISEASE PATHOGENIC VARIANTS AND CANCER SOMATIC MUTATIONS.
    Ma M; Wang C; Glicksberg BS; Schadt EE; Li SD; Chen R
    Pac Symp Biocomput; 2017; 22():473-484. PubMed ID: 27896999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine review: rare driver mutations and their biophysical classification.
    Nussinov R; Jang H; Tsai CJ; Cheng F
    Biophys Rev; 2019 Feb; 11(1):5-19. PubMed ID: 30610579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer driver mutation prediction through Bayesian integration of multi-omic data.
    Wang Z; Ng KS; Chen T; Kim TB; Wang F; Shaw K; Scott KL; Meric-Bernstam F; Mills GB; Chen K
    PLoS One; 2018; 13(5):e0196939. PubMed ID: 29738578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QuaDMutNetEx: a method for detecting cancer driver genes with low mutation frequency.
    Bokhari Y; Alhareeri A; Arodz T
    BMC Bioinformatics; 2020 Mar; 21(1):122. PubMed ID: 32293263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein Structure Readouts of Cancer Drivers for Precision Medicine.
    Dhanjal JK; Kalra RS
    Curr Protein Pept Sci; 2022; 23(3):158-165. PubMed ID: 35331108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of activation and the rewired network: New drug design concepts.
    Nussinov R; Zhang M; Maloney R; Tsai CJ; Yavuz BR; Tuncbag N; Jang H
    Med Res Rev; 2022 Mar; 42(2):770-799. PubMed ID: 34693559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovering potential cancer driver genes by an integrated network-based approach.
    Shi K; Gao L; Wang B
    Mol Biosyst; 2016 Aug; 12(9):2921-31. PubMed ID: 27426053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring preferred amino acid mutations in cancer genes: Applications to identify potential drug targets.
    Anoosha P; Sakthivel R; Michael Gromiha M
    Biochim Biophys Acta; 2016 Feb; 1862(2):155-65. PubMed ID: 26581171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico saturation mutagenesis of cancer genes.
    Muiños F; Martínez-Jiménez F; Pich O; Gonzalez-Perez A; Lopez-Bigas N
    Nature; 2021 Aug; 596(7872):428-432. PubMed ID: 34321661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
    Melloni GE; de Pretis S; Riva L; Pelizzola M; Céol A; Costanza J; Müller H; Zammataro L
    BMC Bioinformatics; 2016 Feb; 17():80. PubMed ID: 26860319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.